Kim N. Chi, MD, presented “TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer” for the Grand Rounds in Urology audience in September, 2019.
How to cite: Chi, Kim N. “TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer” September, 2019. Accessed Dec 2024. https://grandroundsinurology.com/titan-study-leads-to-fda-approval-of-apalutamide-for-patients-with-metastatic-castration-sensitive-prostate-cancer/
TITAN Study Leads to FDA Approval of Apalutamide for Patients with Metastatic Castration-Sensitive Prostate Cancer – Summary:
Kim N. Chi, MD, and E. David Crawford, MD, discuss the findings of the TITAN study regarding the use of apalutamide in patients with castration-sensitive prostate cancer (mCSPC) who are also undergoing androgen deprivation therapy (ADT). Dr. Chi served as principal investigator on this trial and lead author of the article published in The New England Journal of Medicine. These findings led to the FDA approval of apalutamide for these patients on September 17, 2019. The results showed a significant reduction in radiographic progression or death and a reduction in overall risk of death, and therefore support the addition of apalutamide to ADT for a broad range of patients with mCSPC. Apalutamide was initially approved in 2018 for patients with non-metastatic castration-resistant prostate cancer.
ABOUT THE AUTHOR
Kim N. Chi, MD, is a medical oncologist and the Chief Medical Officer and Vice President of BC Cancer, which provides a comprehensive cancer control program for the people of British Columbia, Canada. He is also a Professor of Medicine at the University of British Columbia, as well as a Senior Research Scientist at the Vancouver Prostate Centre. He is Chair of the Genitourinary Disease Site Committee for the Canadian Cancer Trials Group (CCTG) and Co-Chair for the Canadian Uro-Oncology Group (CUOG). Dr. Chi's research is in the area of genitourinary cancers with a focus on prostate cancer and investigational new drugs. This includes outcomes, phase I-III clinical trials, neoadjuvant studies, and mechanisms of treatment resistance. He has received peer-reviewed grant funding from the Canada Institutes of Health Research (CIHR), the National Cancer Institute of Canada (NCIC)/Canadian Cancer Society (CCS), the US Department of Defense, Movember, the Prostate Cancer Foundation (US), and Prostate Cancer Canada.
